Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.55 |
| ▸ | CTSS | P25774 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 4/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9104071 | 1.00 | CTSK (0.55) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL9102877 | 0.96 | CTSK (0.50) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL9102886 | 0.96 | CTSK (0.50) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL9104287 | 0.93 | CTSK (0.52) | CTSKCTSSKMT2AAAK1 | |
| SCHEMBL9104279 | 0.93 | CTSK (0.52) | CTSKCTSSKMT2AAAK1 | |
| SCHEMBL7381049 | 0.88 | CTSK (0.51) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL8021226 | 0.88 | CTSK (0.51) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL7264559 | 0.88 | CTSK (0.53) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL7264560 | 0.88 | CTSK (0.53) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL9658422 | 0.87 | CTSK (0.53) | CTSKCTSSCTSLCTSBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | CTSE, CTSB, CTSS | CTSK 8/4885CTSS 3/4885CTSL 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.